DURECT Operating Expenses 2010-2024 | DRRX

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

DURECT operating expenses from 2010 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

DURECT operating expenses from 2010 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.

Related Stocks
Company Name	Market Cap
Zoetis (ZTS)	$76.9B
Takeda Pharmaceutical (TAK)	$43.9B
Merck (MKKGY)	$20.8B
Astellas Pharma (ALPMY)	$20.2B
Sandoz Group AG (SDZNY)	$19.6B
United Therapeutics (UTHR)	$17.7B
Summit Therapeutics (SMMT)	$15.4B
Neurocrine Biosciences (NBIX)	$12.7B
Shionogi (SGIOY)	$12.3B
Catalent (CTLT)	$10.9B
Madrigal Pharmaceuticals (MDGL)	$7.4B
Jazz Pharmaceuticals (JAZZ)	$6.9B
Orion OYJ (ORINY)	$6.8B
Ionis Pharmaceuticals (IONS)	$5.7B
Corcept Therapeutics (CORT)	$5.7B
Crinetics Pharmaceuticals (CRNX)	$4.7B
PTC Therapeutics (PTCT)	$3.3B
Dyne Therapeutics (DYN)	$3B
Catalyst Pharmaceuticals (CPRX)	$2.7B
Arrowhead Pharmaceuticals (ARWR)	$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.6B
Soleno Therapeutics (SLNO)	$2.2B
NewAmsterdam Pharma (NAMS)	$2B
Recursion Pharmaceuticals (RXRX)	$2B
Centessa Pharmaceuticals (CNTA)	$1.8B
Harrow (HROW)	$1.7B
Ocular Therapeutix (OCUL)	$1.7B
BioCryst Pharmaceuticals (BCRX)	$1.6B
Xencor (XNCR)	$1.6B
Ardelyx (ARDX)	$1.5B